Please ensure Javascript is enabled for purposes of website accessibility

Respironics in Thin Air

By Stephen D. Simpson, Simpson, – Updated Nov 15, 2016 at 7:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Respironics has a great business in the sleep apnea duopoly, but it's still expensive.

As seems to be the case so often with med-tech, quality doesn't come cheap. Oh, sure, you can occasionally find stocks like Kinetic Concepts (NYSE:KCI) that have been marked down because of investor fears, and sometimes the sector as a whole will seem to go to sleep for a bit (as in 2001 or 2002). So when value comes, you'd best grab it.

In the case of today's subject, leading sleep and respiratory company Respironics (NASDAQ:RESP), you have a quality company that seems to be a bit in thin air when it comes to valuation.

Now, the company's fiscal second quarter was plenty good. Sales climbed 14%, the gross margin improved a bit, and net income grew by 20%. Breaking it down a bit further, the large domestic sleep business saw sales up more than 15%, while the hospital business grew almost 13% and the international efforts added 13% growth.

And the industry itself is still in fine shape. It would seem that a large segment of the patient population is untreated -- perhaps in excess of 85% -- so there are still plenty of patients left to treat. Furthermore, the growing obesity trend plays right into Respironics' wheelhouse, because sleep apnea is often a consequence of obesity.

Though rival ResMed (NYSE:RMD) has been making inroads into Respironics' market share, the latter company will soon be rolling out a new system and two new masks, which should help sales. Furthermore, both companies are still well ahead of would-be rivals like Tyco (NYSE:TYC), Vital Signs (NASDAQ:VITL), and Invacare (NYSE:IVC). Respironics also benefits from a clean balance sheet that allows it to make deals and buy new technologies or products.

Even with all those positives in mind, though, I can't really recommend the stock. So it would appear that we have another case of great company/not-so-great stock. But that's the way it often goes in med-tech land -- you get a chance every now and then to get good stocks at good prices, but quality companies don't stay cheap for very long.

For more medical missives:

Tyco is a Motley Fool Inside Value recommendation. Try a 30-day risk-free subscription to the newsletter service that scours the sales rack and finds great stocks at bargain-basement prices.

Fool contributor Stephen Simpson has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tyco International plc Stock Quote
Tyco International plc
TYC
Acelity L.P. Inc. Stock Quote
Acelity L.P. Inc.
KCI.DL
Invacare Corporation Stock Quote
Invacare Corporation
IVC
$0.87 (0.25%) $0.00
ResMed Inc. Stock Quote
ResMed Inc.
RMD
$215.10 (0.28%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.